MA38156B1 - Utilisation du pidotimod pour traiter la dermatite atopique - Google Patents

Utilisation du pidotimod pour traiter la dermatite atopique

Info

Publication number
MA38156B1
MA38156B1 MA38156A MA38156A MA38156B1 MA 38156 B1 MA38156 B1 MA 38156B1 MA 38156 A MA38156 A MA 38156A MA 38156 A MA38156 A MA 38156A MA 38156 B1 MA38156 B1 MA 38156B1
Authority
MA
Morocco
Prior art keywords
pidotimod
atopic dermatitis
treat atopic
acceptable salt
present
Prior art date
Application number
MA38156A
Other languages
English (en)
Other versions
MA38156A1 (fr
Inventor
Federico Mailland
Maurizio Caserini
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of MA38156A1 publication Critical patent/MA38156A1/fr
Publication of MA38156B1 publication Critical patent/MA38156B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention porte sur l'utilisation du pidotimod, ou d'un sel physiologiquement acceptable, pour traiter la dermatite atopique. Dans le cadre du traitement de la présente invention, le pidotimod ou son sel physiologiquement acceptable, est administré de préférence par voie topique.
MA38156A 2012-12-19 2012-12-19 Utilisation du pidotimod pour traiter la dermatite atopique MA38156B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/076086 WO2014094839A1 (fr) 2012-12-19 2012-12-19 Utilisation du pidotimod pour traiter la dermatite atopique

Publications (2)

Publication Number Publication Date
MA38156A1 MA38156A1 (fr) 2016-08-31
MA38156B1 true MA38156B1 (fr) 2017-03-31

Family

ID=47520053

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38156A MA38156B1 (fr) 2012-12-19 2012-12-19 Utilisation du pidotimod pour traiter la dermatite atopique

Country Status (32)

Country Link
US (1) US20150352081A1 (fr)
EP (1) EP2934520B1 (fr)
JP (1) JP6058156B2 (fr)
KR (1) KR20150095772A (fr)
CN (1) CN104797254B (fr)
AU (1) AU2012396941A1 (fr)
BR (1) BR112015011394A2 (fr)
CA (1) CA2889388A1 (fr)
CY (1) CY1118633T1 (fr)
DK (1) DK2934520T3 (fr)
EA (1) EA201591184A1 (fr)
EC (1) ECSP15025570A (fr)
ES (1) ES2615748T3 (fr)
HK (1) HK1210938A1 (fr)
HR (1) HRP20161667T1 (fr)
HU (1) HUE030408T2 (fr)
IL (1) IL239292A0 (fr)
LT (1) LT2934520T (fr)
MA (1) MA38156B1 (fr)
ME (1) ME02559B (fr)
MX (1) MX2015008129A (fr)
PH (1) PH12015501211A1 (fr)
PL (1) PL2934520T3 (fr)
PT (1) PT2934520T (fr)
RS (1) RS55424B1 (fr)
SG (1) SG11201503281QA (fr)
SI (1) SI2934520T1 (fr)
SM (1) SMT201700071B (fr)
TN (1) TN2015000159A1 (fr)
UY (1) UY35197A (fr)
WO (1) WO2014094839A1 (fr)
ZA (1) ZA201502983B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015036009A1 (fr) * 2013-09-10 2015-03-19 Polichem S.A. Pidotimod à utiliser dans le traitement de maladies associées à une inflammation
EP3754806A1 (fr) 2019-06-19 2020-12-23 UTC Fire & Security EMEA BVBA Dispositif d'alimentation électrique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1231723B (it) * 1989-08-11 1991-12-21 Poli Ind Chimica Spa Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono
WO2003043583A2 (fr) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Traitement des troubles immunologiques au moyen des anticorps anti-cd30
EP1688161A1 (fr) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Utilisation du pirlindole dans le traitement des maladies caracterisées par la prolifération des lymphocytes t et/ou par l'hyperproliferation de kerationcytes, notamment la dermatite atopique et le psoriasis
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders

Also Published As

Publication number Publication date
CA2889388A1 (fr) 2014-06-26
PL2934520T3 (pl) 2017-08-31
IL239292A0 (en) 2015-07-30
HRP20161667T1 (hr) 2017-01-27
LT2934520T (lt) 2017-01-10
EP2934520A1 (fr) 2015-10-28
SG11201503281QA (en) 2015-07-30
CN104797254B (zh) 2017-06-06
PT2934520T (pt) 2017-02-16
TN2015000159A1 (en) 2016-10-03
US20150352081A1 (en) 2015-12-10
EP2934520B1 (fr) 2016-11-16
ECSP15025570A (es) 2016-01-29
MA38156A1 (fr) 2016-08-31
ME02559B (fr) 2017-02-20
BR112015011394A2 (pt) 2017-07-11
ES2615748T3 (es) 2017-06-08
HUE030408T2 (en) 2017-05-29
DK2934520T3 (en) 2017-01-23
WO2014094839A1 (fr) 2014-06-26
CN104797254A (zh) 2015-07-22
JP2016503042A (ja) 2016-02-01
AU2012396941A2 (en) 2015-06-18
SMT201700071B (it) 2017-03-08
RS55424B1 (sr) 2017-04-28
SI2934520T1 (sl) 2017-03-31
AU2012396941A1 (en) 2015-05-28
PH12015501211A1 (en) 2015-08-17
JP6058156B2 (ja) 2017-01-11
EA201591184A1 (ru) 2015-10-30
ZA201502983B (en) 2016-11-30
MX2015008129A (es) 2015-09-23
CY1118633T1 (el) 2017-07-12
KR20150095772A (ko) 2015-08-21
HK1210938A1 (en) 2016-05-13
UY35197A (es) 2014-06-30

Similar Documents

Publication Publication Date Title
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
EA201990951A1 (ru) Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
MY189333A (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
MY165160A (en) TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
SG10201804034QA (en) Methods for treating hypotension
WO2016094899A3 (fr) Traitement d'une l'inflammation médiée par hmgb1
AU2017261919A1 (en) Fat and medical uses thereof
CA3010788A1 (fr) Procedes d'administration de vasopresseurs
MA38156B1 (fr) Utilisation du pidotimod pour traiter la dermatite atopique
MA38155B1 (fr) Utilisation du pidotimod pour traiter le psoriasis
FR3019465B1 (fr) Composition hyperosmolaire d'acide hyaluronique et son utilisation pour le traitement de l'oedeme corneen
ZA202006986B (en) Dantrolene formulations and methods of their use
TR201903234T4 (tr) Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti.
EA201790537A1 (ru) Дипептидилкетоамидные соединения и их применение для лечения и/или предотвращения накопления жира
FR2953832B1 (fr) Derives de nouveaux peroxydes, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique pour le traitement ou la prevention de l'acne
FR3008317B1 (fr) Utilisation de microorganismes pour diminuer le taux de trimethylamine dans une cavite du corps humain, notamment pour le traitement de la trimethylaminurie ou d'une vaginose bacterienne et la prevention des maladies cardiovasculaires
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
MA37930A1 (fr) Procédés pour le traitement du cancer utilisant le lipoplatine
MA38455A1 (fr) Utilisation de pidotimodes pour traiter la maladie inflammatoire de l'intestin
MA38456A1 (fr) Utilisation de pidotimode pour traiter le syndrome du côlon irritable
MX2020007183A (es) Inhibidores de ret9 y vegfr2.
FR2953833B1 (fr) Derives de nouveaux peroxydes, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique pour le traitement ou la prevention de l'acne